We are excited to help pave the way, providing evidence of how these medications may impact our patients ocular health. Advertisement Advertisement New insights on effectiveness in patients previously treated with other anti-VEGF drugs CFH gene triggers the eye disease in white patients but not Black patients A primer on sustained release options Study explores association between sleep aid and eye disease Early data show risk is 73% higher in patients with lupus, 40% higher in patients with rheumatoid arthritis Switching medications may decrease treatment burden and macular fluid Why retina specialists should get comfortable with this imaging tool Large retrospective analysis may prompt prospective studies
Neitemeier S, Jelinek A, Laino V, Hoffmann L, Eisenbach I, Eying R, et al
Apr 11 2024;53(3)doi:10.1093/ije/dyae074 Gomes-Neto M, Duraes AR, Conceicao LSR, et al
Zepbound, from drugmaker Eli Lilly, belongs to a new class of medications, called GLP-1 agonists, that have skyrocketed in popularity in the U.S
Implement Resistance Training This is the missing piece for so many people on Ozempic you NEED to strength train from day one
As far as hair loss in women is concerned, they may experience female-pattern baldness
